Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.evotec.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | Buy → Hold | Jefferies | |
| 8/8/2024 | Hold → Sell | Deutsche Bank | |
| 7/29/2024 | $15.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/11/2024 | Buy → Hold | Deutsche Bank | |
| 4/12/2024 | Hold → Buy | Deutsche Bank | |
| 1/18/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 6/23/2023 | $12.00 → $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/16/2023 | $13.00 | Buy → Neutral | BofA Securities |
| 6/8/2023 | Neutral → Buy | Citigroup | |
| 4/4/2023 | $11.00 → $12.00 | Underweight → Equal-Weight | Morgan Stanley |
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining Evotec's Management Board, bringing with her a wealth of experience and expertise in Human Resources leadership.In her role as CPO, Aurélie will oversee the development and implementation of Evotec's people strategy, focusing on fostering a culture of innovation, collaboration, and belonging. With over 25 years of international people leadership experience, Aurélie has a proven track record of driving organisational tra
HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480, NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Board has accepted his resignation from his office.Werner Lanthaler will continue to be available as a strategic advisor to the company's Supervisory Board. Dr Mario Polywka, former COO and currently member of the Supervisory Board has agreed to step in as interim CEO.Evotec confirms guidance 2023.- End of the ad hoc rele
ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITYREPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023HAMBURG, GERMANY / ACCESSWIRE / June 20, 2023 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's virtual Annual General Meeting 2023 with the required majority.Under the topic "Ahead of the curve - leading in our four focus areas", Chief Executive Officer Dr Werner Lanthaler and Chief Financial Officer Laetitia Rouxel presented to the Company's shareholders an update and outlook of Evotec's strategic, scientific, and technological developments,
SC 13D - Evotec SE (0001412558) (Subject)
SC 13G/A - Evotec SE (0001412558) (Subject)
SC 13G/A - Evotec SE (0001412558) (Subject)
SC 13G - Evotec SE (0001412558) (Subject)
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ: EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.Contact: Volker Braun, EVP Head of Global
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ:EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 7
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum PartnersTransaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth driversNew ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec's "Priority Reset" initiative launched in April 2024, which aims to foster profitable
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncologyEvotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the regionJust - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutionsHAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec's Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first
Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. X-Chem's DEL technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, identifying potential start points with high efficiency and precision. In partnership with Evotec's screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to delive
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we
Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G
HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 14 August 2024Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-public
CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTERSTRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEARRESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEGMENTS INTRODUCED: SHARED R&D AND JUST - EVOTEC BIOLOGICSHAMBURG, GERMANY / ACCESSWIRE / May 22, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced financial results and corporate updates for the first quarter 2024.HIGHLIGHTSEVOTEC'S TRANSACTIONAL BUSINESS IMPACTED BY HEADWINDS; STRONG GROWTH IN JUST - EVOTEC BIO
HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast details Date: Wednesday, 22 May 2024 Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link .The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCEPRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 MEVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST - EVOTEC BIOLOGICS” STARTING Q1 2024 HAMBURG, GERMANY / ACCESSWIRE / April 24, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.CONTIN
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 24 April 2024 Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join via phone, please pre-register
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.During the call, the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich and Evotec's CEO Dr Mario Polywka will offer the Company's perspective on its commitment to comply with highest Corporate Governance standards and its dedication to well-balanced and transparent communication to all market participants. The statement will be limited to Evotec's scope of influence.Dr Mario Polywka will also share management's conviction to execute on
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETSPARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERSPIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATIONALL ELEMENTS OF GUIDANCE CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2023.HIGHLIGHTSEVOTEC'S TOPLINE SUCCESS REFLECTS STRONG DEMANDGroup revenues increased by 14% (19% excluding fx-effects) to € 580.1 m (9M 2022: € 510.8 m); excluding a lower contribution from milestones, upfronts and license payments, Base business at € 575.3 m (9M 2022: € 502.8
Jefferies downgraded Evotec SE from Buy to Hold
Deutsche Bank downgraded Evotec SE from Hold to Sell
Morgan Stanley downgraded Evotec SE from Overweight to Equal-Weight and set a new price target of $6.00 from $15.00 previously
Deutsche Bank downgraded Evotec SE from Buy to Hold
Deutsche Bank upgraded Evotec SE from Hold to Buy
RBC Capital Mkts upgraded Evotec SE from Sector Perform to Outperform
Morgan Stanley upgraded Evotec SE from Equal-Weight to Overweight and set a new price target of $16.00 from $12.00 previously
BofA Securities downgraded Evotec SE from Buy to Neutral and set a new price target of $13.00
Citigroup upgraded Evotec SE from Neutral to Buy
Morgan Stanley upgraded Evotec SE from Underweight to Equal-Weight and set a new price target of $12.00 from $11.00 previously
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Delta Air Lines, Inc. (NYSE:DAL) fell sharply in today's pre-market trading after the company posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook. Delta Air Lines reported quarterly earnings of $2.36 per share which missed the analyst consensus estimate of $2.37 per share. The company reported quarterly sales of $16.658 billion which beat the analyst consensus estimate of $15.452 billion, according to data from Benzinga Pro. Delta Air Lines shares fell 9% to $42.65 in the pre-market trading session. Here are some big stoc
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases The research will be carried out at Evotec's sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programs.
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company’s vulnerability to a takeover. Multiple buyout firms are reportedly evaluating Hamburg-based Evotec as a potential acquisition target, initiating early discussions with advisers to assess the company’s drug pipeline and strategic value. Evotec’s shares surged. The spike follows a year-to-date decline of over 60%, with the stock recently hitting its lowest since March 2017. The drop came after Intron Health analysts downgraded the stock from “buy” to “sell.” Bloomberg noted, citing sources, that despite the market activ
- Bloomberg
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia. Nurix Therapeutics shares jumped 12.1% to $17.01 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) rose 89.4% to $6.61 in pre-market trading after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity. Interactive Strength Inc. (NASDAQ:TR
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes. AMC Networks shares dipped 9.4% to $14.24 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading. Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday. Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.
Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
20-F - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
NT 20-F - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)
6-K - Evotec SE (0001412558) (Filer)